Equities research analysts at Wells Fargo & Co. (NYSE: WFC) started coverage on shares of Medidata Solutions (NASDAQ: MDSO) in a research note issued to investors on Wednesday. The firm set an “outperform” rating on the stock.
Several other analysts have also recently commented on the stock. Analysts at Needham & Company reiterated a “buy” rating on shares of Medidata Solutions in a research note to investors on Wednesday, May 2nd. Separately, analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Medidata Solutions from $31.00 to $34.00 in a research note to investors on Wednesday, May 2nd. Finally, analysts at Raymond James (NYSE: RJF) upgraded shares of Medidata Solutions from a “market perform” rating to an “outperform” rating in a research note to investors on Friday, April 20th.
Medidata Solutions traded up 0.79% on Wednesday, hitting $27.98. Medidata Solutions has a 1-year low of $14.07 and a 1-year high of $27.96. The company has a market cap of $678.5 million and a price-to-earnings ratio of 17.14.
Medidata Solutions last released its earnings data on Tuesday, May 1st. The company reported $0.26 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.22 by $0.04. Medidata Solutions’s revenue was up 23.5% compared to the same quarter last year. Analysts expect that Medidata Solutions will post $0.31 EPS next quarter.
Medidata Solutions, Inc. (Medidata) is a provider of hosted clinical development solutions. The Company’s customers include pharmaceutical, biotechnology and medical device companies, academic institutions, contract research organizations (CROs), and other organizations engaged in clinical trials.